EXD-12 is a live attenuated herpes simplex vaccine candidate. EXD-12 is going to be tested as a prophylactic and therapeutic vaccine candidate in the guinea pig model.
EXD-12 is currently in preclinical testing for safety and efficacy as both a prophylactic and therapeutic vaccine for both Herpes Simplex Virus-1, HSV-1, and Herpes Simplex Virus-2, HSV-2.
New data indicates that glycoprotein D acts as a decoy, so the immune system is not able to form an effective antibody response to other antigens. Without glycoprotein D, Herpes is visible to the immune system and is also unable to spread between cells.